2022年4月,PheastTherapeutics宣布完成7600万美元A轮融资,该公司的创始人为CD24别吃我信号通路的发现者Irv Weissman教授。 德琪医药在去年SITC会议上披露了ATG-031的临床前研究数据。ATG-031可以有效阻断CD24与Siglec-10的相互作用,IC50为13.12nM。功能学研究表明,ATG-031可以有效增强TAM对肿瘤细胞的吞噬效应。 小鼠肿...
作为一个新型固有免疫检查点,CD24通过与表达于肿瘤相关巨噬细胞(TAM)上的抑制受体Siglec-10(唾液酸结合性免疫球蛋白样凝集素10)的相互作用,实现肿瘤细胞的免疫逃逸。在2023年美国癌症研究协会年会(AACR 2023)和2022年癌症免疫治疗学会年会(SITC 2022)上公布的临床前数据显示,ATN-031可以纳摩尔级别亲和力与CD24特异性...
doi:10.1136/jitc-2022-SITC2022.0482Background By overexpressing anti-phagocytic surface proteins, often known as "don't eat me" signals, cancer cells can evade macrophage-mediated elimination. Therapeutic antibodies targeting "don't eat me" protein, such as CD47, demonstrates promising anti-tumor ...
doi:10.1136/jitc-2023-SITC2023.1337Background CD24 is a small, highly glycosylated cell adhesion protein that functions as a novel 'don't eat me' target in cancer, where it is the dominant innate immune checkpoint.1 Through its interaction with Siglec-10 expressed by tumor-associated macrophages...